BiotechTube

SHR-1209

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypercholesterolemia and Hyperlipidemia

Conditions

Hypercholesterolemia and Hyperlipidemia

Trial Timeline

May 25, 2022 → Dec 31, 2022

NCT ID
NCT05370950

About SHR-1209

SHR-1209 is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Hypercholesterolemia and Hyperlipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT05370950. Target conditions include Hypercholesterolemia and Hyperlipidemia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (2)

NCT IDPhaseStatus
NCT05370950Phase 1Completed
NCT04455581Phase 2UNKNOWN

Competing Products

20 competing products in Hypercholesterolemia and Hyperlipidemia

See all competitors
ProductCompanyStageHype Score
Evacetrapib + Ezetimibe + Atorvastatin + PlaceboEli LillyPhase 3
77
generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)YuhanApproved
85
Rosuvastatin+Ezetimibe + RosuvastatinYuhanApproved
85
colesevelam HCl tablets, and simvastatin tablets + simvastatin tablets and colesevelam HCl placeboDaiichi SankyoApproved
85
colesevelam HCl tablets and fenofibrate tablets + fenofibrate tablets and Welchol placebo tablets + fenofibrate tablets and Welchol placebo tabletsDaiichi SankyoApproved
85
colesevelam HCl + placeboDaiichi SankyoApproved
85
Bempedoic acid and/or its fixed-dose combination with ezetimibeDaiichi SankyoPre-clinical
23
colesevelam HCl tablets, and atorvastatin tablets + colesevelam HCl placebo tablets and atorvastatin tabletsDaiichi SankyoApproved
85
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
85
Bempedoic Acid 180Mg/Ezetimibe 10Mg TabDaiichi SankyoPre-clinical
23
Colesevelam Hydrochloride + Ezetimibe + SimvastatinDaiichi SankyoApproved
85
pravastatin tablets and Welchol tablets + pravastatin tablets and Welchol placebo tabletsDaiichi SankyoApproved
85
Bempedoic acid and/or its fixed dose combination with ezetimibeDaiichi SankyoPre-clinical
23
atrovastatinAstellas PharmaPre-clinical
23
Pitavastin 4mg + Atorvastatin 20mg + Rosuvastatin 5mgEli LillyApproved
85
PPAR alpha + atorvastatin + placeboEli LillyPhase 2
52
Evacetrapib + PlaceboEli LillyPhase 3
77
LY3015014 + Placebo + Statin + EzetimibeEli LillyPhase 2
52
SHR-1209 single-site subcutaneous injection + SHR-1209 multiple-site subcutaneous injectionsJiangsu Hengrui MedicinePhase 1
33
SHR-1209Jiangsu Hengrui MedicinePhase 2
52

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85